Skip to main content

Biosimilar changes ASP outpacing reimbursement making not affordable to use Working with CMS but needs further legislati

Social Author Name
Eric Dein
Tweet Content
Biosimilar changes ASP outpacing reimbursement making not affordable to use Working with CMS but needs further legislation to fix this FDA may change interchangeability status for medications to no longer require switching studies @ACRheumDC @RheumNow #ACR24 https://t.co/daYQJvsHRG
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×